N/A
N=480
Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Bottom Line
View on ClinicalTrials.gov: NCT02013180 ↗Enrolled (actual)
480
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- Male
- Sponsor
- Bagcilar Training and Research Hospital
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases |
150.8; 239.6 | — |
Summary
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease.
In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease.
In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.
Eligibility Criteria
Inclusion Criteria
Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination
Exclusion Criteria
usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.
Data sourced from ClinicalTrials.gov (NCT02013180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.